KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
9/30/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 860.2% | – | – | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 91% | 58.6% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -308.2% | -3,798.4% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -361.4% | -4,214.3% | – | – |
| EPS Diluted | -0.92 | -1.12 | -1.05 | -0.92 |
| % Growth | 17.9% | -6.7% | -14.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |